| 英文别名 |
GSK-3β Inhibitor II;GSK-3 Inhibitor II;PYRIDINE, 4-[5-[[(3-IODOPHENYL)METHYL]THIO]-1,3,4-OXADIAZOL-2-YL]-;2-(3-iodobenzylthio)-5-(pyridin-4-yl)-1,3,4-oxadiazole;2-thio(3-iodobenzyl)-5-(1-pyridyl)-[1,3,4]oxadiazole;2-Thio(3-iodobenzyl)-5-(1-pyridyl)-[1,3,4]-oxadiazole;AC1O702O;CHEMBL288064;CTK8E9270;Glycogen Synthase Kinase-3beta Inhibitor II;GSK-3b Inhibitor II;GSK-3beta Inhibitor II;HMS3229G14;SureCN5022122;GSK3β inhibitor II;HY-14679;CS-0003507;478482-75-6;TIBPO;HMS3265F18;MS-26647;CHEBI:91342;K00026;GSK3beta Inhibitor II;GSK-3beta Inhibitor II?;G65367;2-[(3-iodophenyl)methylsulfanyl]-5-pyridin-4-yl-1,3,4-oxadiazole;Z2216900420;4-(5-{[(3-iodophenyl)methyl]sulfanyl}-1,3,4-oxadiazol-2-yl)pyridine;DTXSID10424894;SDCCGSBI-0086753.P003;oxadiazole-pyridyl containing compound 12;BDBM8552;GTPL5978;Pyridine,4-[5-[[(3-iodophenyl)methyl]thio]-1,3,4-oxadiazol-2-yl]-;2-((3-Iodobenzyl)thio)-5-(pyridin-4-yl)-1,3,4-oxadiazole;Q27077899;DA-53751;SCHEMBL5022122;HMS3265E18;HMS3265E17;HMS3265F17;gsk-3? inhibitor II;HSCI1_000107;A Inhibitor II;2-{[(3-iodophenyl)methyl]sulfanyl}-5-(pyridin-4-yl)-1,3,4-oxadiazole;GSK3;BRD-K09991945-001-01-2;2-[(3-iodophenyl)methylsulfanyl]-5-(4-pyridyl)-1,3,4-oxadiazole;CCG-206842 |